Navigation Links
Phase Genomics Proximo Hi-C Technology Featured in Nature Genetics
Date:3/6/2017

Today, an article co-authored by founders of Phase Genomics was published in Nature Genetics, summarizing the assembly of the most contiguous de novo mammalian genome to-date. The ultra-long-range scaffolds in this goat genome were made possible by Phase Genomics’ revolutionary genome scaffolding technology now called Proximo™ Hi-C – the first commercial offering of in vivo Hi-C based genome assembly and the commercial successor to the Lachesis method described in the article. The study was spearheaded by a group of researchers from the USDA, NHGRI, and Virginia State University, together with Phase Genomics and other commercial entities.

“We are pleased to have the opportunity to share the results of this groundbreaking project with Nature Genetics readers,” said company CEO, Ivan Liachko. “This paper highlights a fundamental advancement in genome assembly and I'm thrilled to see the animal community gain such an amazing resource.”

The Proximo Hi-C scaffolding platform is the fastest and most affordable solution for end-to-end scaffolding of de novo genomes. Genomes assembled without this process are fragmented and often omit critical biological information.

For this project, Pacific Biosciences long-read shotgun sequencing, Illumina short reads, and BioNano Irys optical mapping were used to generate a draft assembly. The Proximo Hi-C process was then used in combination with custom analysis to create chromosome-level scaffolds.

“We saw similar results in our work with Phase Genomics on plants and look forward to publishing similar outcomes soon,” said Prof. Jeff Maughan, a plant researcher at Brigham-Young University. “The level of genome completeness and contiguity yielded by this technology has transformed how we view genome projects and has enabled us to ask new biological questions.”

Interested parties can learn more about Proximo Hi-C and other Phase Genomics services by visiting their website at http://www.phasegenomics.com.

Read the full story at http://www.prweb.com/releases/2017/03/prweb14121855.htm.


'/>"/>
Source: PRWeb
Copyright©2017 Vocus, Inc.
All rights reserved


Related biology technology :

1. SELLAS Life Sciences Announces Updated Positive Phase 2 Data Reinforcing Meaningful Clinical Benefit of its WT1 Immunotherapeutic Anti-cancer Treatment in Multiple Myeloma Patients
2. OncoGenex Pharmaceuticals, Inc. Announces Phase 2 Apatorsen Data for Two Clinical Trials Presented at the American Society of Clinical Oncology (ASCO) 2017 Genitourinary Cancers Symposium
3. BERG Initiates Phase I/II Monotherapy Trial of BPM 31510-IV in Patients with Glioblastoma Multiforme (GBM)
4. VM BioPharma Announces Publication of Phase 1/2 Clinical Data of Novel Gene Therapy VM202 in Amyotrophic Lateral Sclerosis (ALS)
5. OncoSec to Present New Clinical Data from Phase 2 Combination Study at ASCO-SITC Clinical Immuno-Oncology Symposium and Corporate Updates at Two Investment Conferences in February
6. Sirnaomics Initiates a Clinical Phase IIa Study of Its Leading siRNA Therapeutic Candidate, STP705, for Treatment of Hypertrophic Scar
7. Envisia Therapeutics Releases Interim ENV515 (Travoprost XR) Phase 2 Data Demonstrating 11-Month Duration-of-Action After a Single Dose in Patients With Glaucoma
8. Roche selects Vivonoetics to provide advanced respiratory assessment for the FIREFISH Phase II multicenter clinical trial in infants with Spinal Muscular Atrophy Type 1.
9. Protagonist Therapeutics Initiates Phase 2b Study of Oral Drug Candidate PTG-100 in Ulcerative Colitis
10. Phase Genomics Announces Commercial Availability of Rapid End-to-End Genome Assembly Service
11. Symbios Announces National Science Foundation SBIR Phase IIB Award to Commercialize Plasma Oxidation Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... , Belgium , March 28, 2017 ... VolitionRx Limited (NYSE MKT: VNRX), today announced the engagement of ... DVD Associates, LLC, as a strategic consultant. Dr. Vollmer ... identifying and securing non-dilutive funding in the State ... United States . Dr. Vollmer Dahlke has ...
(Date:3/28/2017)... -- Biostage, Inc. (Nasdaq: BSTG), ("Biostage" or ... to treat cancers and other life-threatening conditions of the ... McGorry, CEO of Biostage, will present on the ... MassBio 2017 Annual Meeting on Thursday, March ... The 3D Printing and BioEngineering panel will ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... its brand-new, fully-certified hygienic SWB805 MultiMountTM weigh modules. These weigh modules are ... certified by National Sanitation Foundation (NSF). , As fully integrated weighing solutions, ...
(Date:3/27/2017)... , March 27, 2017 Roka Bioscience, Inc. ... testing solutions for the detection of foodborne pathogens,  today announced ... Sidoti & Company Spring 2017 Convention on March 29 at ... York Marriott Marquis. About Roka Bioscience ... Roka ...
Breaking Biology Technology:
(Date:3/27/2017)... , March 27, 2017  Catholic Health Services ... Management Systems Society (HIMSS) Analytics for achieving Stage ... Model sm . In addition, CHS previously earned ... hospitals using an electronic medical record (EMR). ... high level of EMR usage in an outpatient ...
(Date:3/23/2017)... India , March 23, 2017 The report "Gesture ... Touchless Biometric), Industry, and Geography - Global Forecast to 2022", published by MarketsandMarkets, ... at a CAGR of 29.63% between 2017 and 2022. ... ... ...
(Date:3/22/2017)... , March 21, 2017 Optimove ... used by retailers such as 1-800-Flowers and AdoreMe, ... — Product Recommendations and Replenishment. Using Optimove,s machine learning ... personalized product and replenishment recommendations to their customers ... on predictions of customer intent drawn from a ...
Breaking Biology News(10 mins):